title: Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics".
authors.affiliation: Department of Clinical Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Norway and Oslo University.
authors.forename: Erik Fink
authors.initials: EF
authors.lastname: Eriksen
authors.affiliation: Laval University, Quebec City, Canada; CHU de Québec (CHUL) Research Centre, Quebec City, Canada.
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Brown
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents; D003358:Cosmetics; D006801:Humans; D010024:Osteoporosis; D010281:Parathyroid Hormone; D019379:Teriparatide
chemical_list: D050071:Bone Density Conservation Agents; D003358:Cosmetics; D010281:Parathyroid Hormone; D019379:Teriparatide
keywords: Concurrent therapy; Denosumab; Osteoporosis; Parathyroid hormone; Teriparatide